Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.2K
Overview
33.2K
Vaccinations01:51

Vaccinations

52.1K
Overview
52.1K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Meeting of the Société de pathologie exotique - Limoges Institute of Tropical Neurology, 23rd April 2010. Dementia in the tropics. Epilepsy in the tropics].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[Chagas disease].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[The bulletin of the SPE: continuity within change].

Bulletin de la Societe de pathologie exotique (1990)·2010
Same author

[Centenary of the Society of Exotic Pathology . Introduction ].

Bulletin de la Societe de pathologie exotique (1990)·2008
Same author

[Sleep disorders and hypnotic agents: a real public health issue].

Annales pharmaceutiques francaises·2007
Same author

[Genomic, molecular biology and malaria: new medical perspectives?].

Bulletin de la Societe de pathologie exotique (1990)·2004
Same journal

[Cannabis use in a central region of Tunisia].

Sante (Montrouge, France)·2012
Same journal

[Factors associated with overweight and obesity in children in Ouagadougou (Burkina Faso)].

Sante (Montrouge, France)·2012
Same journal

[Epidemiology, microbiology, and outcomes of septicemia in children treated at the Charles de Gaulle University Pediatric Hospital in Burkina Faso].

Sante (Montrouge, France)·2012
Same journal

[Medical audit of neonatal deaths with the "three delay" model in a pediatric hospital in Ouagadougou].

Sante (Montrouge, France)·2012
Same journal

[Controlling caesarean-site infection. Collaboration between the obstetric and hospital hygiene departments].

Sante (Montrouge, France)·2012
Same journal

[Sickle cell disease is one century old: what about therapeutics?].

Sante (Montrouge, France)·2012
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
08:20

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes

Published on: August 17, 2022

2.7K

[Antimalarial vaccination]

P Ambroise-Thomas1

  • 1Département de parasitologie-mycologie médicale et moléculaire, CNRS EP 78, Faculté de Médecine de Grenoble.

Sante (Montrouge, France)
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Developing malaria vaccines is challenging due to antigen complexity. Early vaccine trials failed, but the SPf 66 antigen showed partial success, offering 30-50% protection against malaria in humans.

More Related Videos

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
08:46

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Published on: May 18, 2016

18.4K
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

23.8K

Related Experiment Videos

Last Updated: Feb 22, 2026

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
08:20

In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes

Published on: August 17, 2022

2.7K
Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
08:46

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Published on: May 18, 2016

18.4K
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

23.8K

Area of Science:

  • Malariology
  • Vaccinology
  • Immunology

Context:

  • Malaria vaccine development faces significant hurdles due to complex and variable Plasmodium falciparum antigens and imperfect experimental models.
  • Despite extensive research over 20 years, numerous vaccine trials targeting different parasite stages (sporozoites, merozoites, gametocytes) have historically failed.

Purpose:

  • To review the historical challenges and recent advancements in malaria vaccine development.
  • To highlight the partial success of the synthetic antigen SPf 66 in human trials and discuss future directions.

Summary:

  • The synthetic antigen SPf 66, developed by Patarroyo and collaborators, represents the first partially successful malaria vaccine in humans, demonstrating 30-50% protection against the disease in trials in South America and East Africa.
  • These trials evaluated vaccine efficacy based on reduced morbidity, not just parasitemia, marking a crucial step forward despite modest results.
  • Future vaccine strategies may include anti-DNA vaccines and other novel approaches, with the expectation of more efficient vaccines becoming available in the coming years.

Impact:

  • The SPf 66 vaccine trial signifies a breakthrough, offering the first human protection against malaria and paving the way for future vaccine development.
  • While promising, malaria vaccines are not a sole solution for eradication; integrated control strategies including vector control, prophylaxis, and therapy are essential for managing this complex disease.
  • Continued research and development are expected to yield more effective malaria vaccines, but realistic expectations regarding timelines and impact are necessary.